ES2170649B1 - Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica. - Google Patents

Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.

Info

Publication number
ES2170649B1
ES2170649B1 ES200000765A ES200000765A ES2170649B1 ES 2170649 B1 ES2170649 B1 ES 2170649B1 ES 200000765 A ES200000765 A ES 200000765A ES 200000765 A ES200000765 A ES 200000765A ES 2170649 B1 ES2170649 B1 ES 2170649B1
Authority
ES
Spain
Prior art keywords
cdp
treatment
hill
abstinence
alcoholic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200000765A
Other languages
English (en)
Spanish (es)
Other versions
ES2170649A1 (es
Inventor
Ambros Rafael Foguet
Massana Jorge Ramentol
Fernandez De Pinedo Raf Lozano
Sanchez Julian Agut
Herrera Jesus Torres
Carreno Manuel Mauricio Raga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Original Assignee
Ferrer Internacional SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200000765A priority Critical patent/ES2170649B1/es
Application filed by Ferrer Internacional SA filed Critical Ferrer Internacional SA
Priority to CA002402707A priority patent/CA2402707C/en
Priority to PCT/EP2001/003536 priority patent/WO2001072288A2/en
Priority to US10/240,159 priority patent/US6894032B2/en
Priority to EP01936147A priority patent/EP1267892B1/en
Priority to IL15116301A priority patent/IL151163A0/xx
Priority to JP2001570249A priority patent/JP4724348B2/ja
Priority to PT01936147T priority patent/PT1267892E/pt
Priority to PL363177A priority patent/PL199291B1/pl
Priority to NZ520825A priority patent/NZ520825A/en
Priority to DE60106890T priority patent/DE60106890T2/de
Priority to KR1020027012966A priority patent/KR100794891B1/ko
Priority to AU6214101A priority patent/AU6214101A/xx
Priority to AT01936147T priority patent/ATE281172T1/de
Priority to MXPA02009442A priority patent/MXPA02009442A/es
Priority to CZ20023245A priority patent/CZ298933B6/cs
Priority to AU2001262141A priority patent/AU2001262141B2/en
Priority to RU2002129579/15A priority patent/RU2251422C2/ru
Priority to DK01936147T priority patent/DK1267892T3/da
Priority to BR0109477-7A priority patent/BR0109477A/pt
Publication of ES2170649A1 publication Critical patent/ES2170649A1/es
Priority to ZA200206349A priority patent/ZA200206349B/en
Priority to IL151163A priority patent/IL151163A/en
Priority to NO20024574A priority patent/NO329766B1/no
Application granted granted Critical
Publication of ES2170649B1 publication Critical patent/ES2170649B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ES200000765A 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica. Expired - Fee Related ES2170649B1 (es)

Priority Applications (23)

Application Number Priority Date Filing Date Title
ES200000765A ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
AT01936147T ATE281172T1 (de) 2000-03-29 2001-03-28 Verwendung von cdp-choline zur behandlung des alkoholentzugsyndroms
US10/240,159 US6894032B2 (en) 2000-03-29 2001-03-28 Use of CDP-choline for the treatment of alcohol withdrawal syndrome
EP01936147A EP1267892B1 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
IL15116301A IL151163A0 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
JP2001570249A JP4724348B2 (ja) 2000-03-29 2001-03-28 アルコール禁断症状を治療するためのｃｄｐ−コリンの使用
PT01936147T PT1267892E (pt) 2000-03-29 2001-03-28 Utilizacao de cdp-colina para o tratamento do sindrome de abstinencia de alcool
PL363177A PL199291B1 (pl) 2000-03-29 2001-03-28 Zastosowanie CDP-choliny do leczenia zespołu odstawienia alkoholu
NZ520825A NZ520825A (en) 2000-03-29 2001-03-28 CDP-choline (cytidine diphosphate choline, citicoline) for the treatment of alcohol withdrawal syndrome
DE60106890T DE60106890T2 (de) 2000-03-29 2001-03-28 Verwendung von cdp-cholin zur behandlung des alkoholentzugsyndroms
KR1020027012966A KR100794891B1 (ko) 2000-03-29 2001-03-28 씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법
CZ20023245A CZ298933B6 (cs) 2000-03-29 2001-03-28 Farmaceutický prostredek
CA002402707A CA2402707C (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
MXPA02009442A MXPA02009442A (es) 2000-03-29 2001-03-28 Uso de la cdp-colina en el tratamento del sindrome de la abstinencia alcoholica.
AU6214101A AU6214101A (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
AU2001262141A AU2001262141B2 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
RU2002129579/15A RU2251422C2 (ru) 2000-03-29 2001-03-28 Cdp-холин-средство для лечения синдрома алкогольной абстиненции и способ лечения с его использованием
DK01936147T DK1267892T3 (da) 2000-03-29 2001-03-28 Anvendelse af CDP-cholin til behandling af alkoholabstinenssyndrom
BR0109477-7A BR0109477A (pt) 2000-03-29 2001-03-28 Uso de cdp-colina para o tratamento da sìndrome da supressão do álcool
PCT/EP2001/003536 WO2001072288A2 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
ZA200206349A ZA200206349B (en) 2000-03-29 2002-08-08 Use of CDP-Choline for the treatment of alcohol withdrawal syndrome.
IL151163A IL151163A (en) 2000-03-29 2002-08-09 Use of cdp-choline for the preparation of a medicament for treating alcohol withdrawal syndrome
NO20024574A NO329766B1 (no) 2000-03-29 2002-09-24 Anvendelse av CDP-kolin for fremstilling av medikament for behandling av alkoholabstinens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200000765A ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.

Publications (2)

Publication Number Publication Date
ES2170649A1 ES2170649A1 (es) 2002-08-01
ES2170649B1 true ES2170649B1 (es) 2003-06-16

Family

ID=8492914

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200000765A Expired - Fee Related ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.

Country Status (21)

Country Link
US (1) US6894032B2 (enExample)
EP (1) EP1267892B1 (enExample)
JP (1) JP4724348B2 (enExample)
KR (1) KR100794891B1 (enExample)
AT (1) ATE281172T1 (enExample)
AU (2) AU2001262141B2 (enExample)
BR (1) BR0109477A (enExample)
CA (1) CA2402707C (enExample)
CZ (1) CZ298933B6 (enExample)
DE (1) DE60106890T2 (enExample)
DK (1) DK1267892T3 (enExample)
ES (1) ES2170649B1 (enExample)
IL (2) IL151163A0 (enExample)
MX (1) MXPA02009442A (enExample)
NO (1) NO329766B1 (enExample)
NZ (1) NZ520825A (enExample)
PL (1) PL199291B1 (enExample)
PT (1) PT1267892E (enExample)
RU (1) RU2251422C2 (enExample)
WO (1) WO2001072288A2 (enExample)
ZA (1) ZA200206349B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
EP1541154A1 (en) * 2002-07-11 2005-06-15 Yamasa Corporation Medicinal composition for drug-induced neuropathy
CN100430066C (zh) 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
AU2003299715A1 (en) * 2002-12-20 2004-07-22 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
WO2006020703A1 (en) 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
RU2072239C1 (ru) * 1991-01-11 1997-01-27 Институт биохимии СО РАМН Способ коррекции метаболической зависимости от алкоголя и средство л.е.панина для его осуществления
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
CA2193967C (en) * 1994-07-01 2007-09-11 Reid W. Von Borstel Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
KR100217488B1 (ko) * 1997-06-03 1999-09-01 맹섭 골프채의 헤드커버
RU2127589C1 (ru) * 1997-06-03 1999-03-20 Порембский Ярослав Олегович Способ лечения стрессорных поражений нервной системы
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
DK1267892T3 (da) 2005-03-07
EP1267892B1 (en) 2004-11-03
NO20024574L (no) 2002-11-22
ES2170649A1 (es) 2002-08-01
ATE281172T1 (de) 2004-11-15
WO2001072288A3 (en) 2002-05-10
EP1267892A2 (en) 2003-01-02
MXPA02009442A (es) 2003-02-12
PT1267892E (pt) 2005-03-31
US6894032B2 (en) 2005-05-17
CZ298933B6 (cs) 2008-03-12
NZ520825A (en) 2004-04-30
BR0109477A (pt) 2003-06-03
KR20030005248A (ko) 2003-01-17
PL199291B1 (pl) 2008-09-30
AU6214101A (en) 2001-10-08
KR100794891B1 (ko) 2008-01-14
DE60106890T2 (de) 2005-11-03
NO329766B1 (no) 2010-12-13
PL363177A1 (en) 2004-11-15
ZA200206349B (en) 2003-08-08
WO2001072288A2 (en) 2001-10-04
US20030162749A1 (en) 2003-08-28
CA2402707A1 (en) 2001-10-04
NO20024574D0 (no) 2002-09-24
IL151163A0 (en) 2003-04-10
JP4724348B2 (ja) 2011-07-13
RU2002129579A (ru) 2004-03-27
RU2251422C2 (ru) 2005-05-10
DE60106890D1 (de) 2004-12-09
AU2001262141B2 (en) 2005-03-10
CZ20023245A3 (cs) 2003-03-12
IL151163A (en) 2011-01-31
JP2003528133A (ja) 2003-09-24
CA2402707C (en) 2007-11-13

Similar Documents

Publication Publication Date Title
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
MXPA03005464A (es) Agentes antivirales.
BR0015188A (pt) Composições farmacêuticas
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
BR0213358A (pt) Uso de flibanserina
BRPI9713596C1 (pt) novas preparações de medicamentos aquosas para a obtenção de aerossóis livres de gás propelente.
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
LT2001119A (en) Pharmaceutical formulations comprising intranasal morphine and use thereof
AR030857A1 (es) Derivados nitroso de difenolaminas, composiciones farmaceuticas que los contienen y su uso en la preparacion de productos medicinales
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
DE50105771D1 (de) Ibuprofen-wirkstoffzubereitung
YU53402A (sh) Preparat
HRP20070476T3 (en) Treatment of dependence withdrawal
SE0102440D0 (sv) New compound
ES2170649B1 (es) Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides
ES2136581B1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
WO2002004012A8 (en) Anhydrous pharmaceutical composition of vancomycin for topical use
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
BR9914125A (pt) Composições farmacêuticas baseadas em alfa-ciclodextrina para administração oral de análogos lh-rh

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020801

Kind code of ref document: A1

Effective date: 20020801

FG2A Definitive protection

Ref document number: 2170649B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20211122